BioMS SPMS drug

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

BioMS SPMS drug

Postby HarryZ » Wed Mar 08, 2006 9:44 am

The following is an update from BioMS on their SPMS drug that they have been working on for over 5 years now. It's one of the few drugs for SPMS that anyone has spent much time on.

Harry

____________________

BioMS Medical's MBP8298 shows five-year delay of disease progression in patients with multiple sclerosis

-Results to be presented at the American Academy of Neurology April 4,
2006-

Toronto Stock Exchange Symbol: MS

EDMONTON, March 7 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS patients, had a median time to disease progression (worsening) of 78 months compared to 18 months for patients who received placebo.

"These results show an unprecedented 5-year improvement in time to
disease progression in the majority of progressive MS patients," said Kevin Giese, President and CEO of BioMS Medical. "Pending confirmation of these results in our ongoing international pivotal trial in secondary progressive MS, we anticipate that MBP8298 will represent a novel first in class treatment for MS patients."

The findings are based on a two-year treatment and five-year follow-on study conducted and analyzed by the University of Alberta and BioMS Medical. The primary objective of the trial was to assess the clinical efficacy of 500mg of MBP8298 administrated intravenously every six months, as measured by the Expanded Disability Status Scale (EDSS). Long-term follow-up treatment and assessment of 20 progressive MS patients with the HLA-DR2 or HLA-DR4 immune response genes demonstrated a median time to progression of 78 months (6.5 years) for MBP8298 treated patients compared to 18 months (1.5 years) for patients treated with placebo in the initial study (Kaplan-Meier analysis, p equals 0.004). Details of the study and its findings will be presented at the 58th
Annual Meeting of the American Academy of Neurology on April 4, 2006 in
San Diego, CA.

Phase II/III Pivotal Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomized, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS). To date the trial has successfully completed three safety reviews by its independent Data Safety Monitoring Board.
User avatar
HarryZ
Family Elder
 
Posts: 2320
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada

Advertisement

Postby mrhodes40 » Wed Mar 08, 2006 10:32 am

Wow thanks for posting this. THANK GOD! Somebody finally making the treatment end point the EDSS scale and not "reduction of activating lesions''.

there is more about what this is here http://www.mult-sclerosis.org/news/Mar2001/MBP8298.html

Marie
User avatar
mrhodes40
Family Elder
 
Posts: 2066
Joined: Thu Sep 23, 2004 3:00 pm
Location: USA

Postby bromley » Wed Mar 08, 2006 1:54 pm

Harry Z,

This is yesterday's news - see drugs pipeline.

I expect you saw it late as you were on the phone to your broker ready to sell your Biogen shares.

Ian :D
User avatar
bromley
Family Elder
 
Posts: 1889
Joined: Fri Sep 10, 2004 3:00 pm

Postby Arron » Wed Mar 08, 2006 2:13 pm

now now... ;)
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.
User avatar
Arron
Volunteer Moderator
 
Posts: 892
Joined: Sun Feb 01, 2004 4:00 pm
Location: California, USA

Postby bromley » Wed Mar 08, 2006 2:41 pm

Arron,

I add those silly faces now to show that I am joking!

Ian
User avatar
bromley
Family Elder
 
Posts: 1889
Joined: Fri Sep 10, 2004 3:00 pm

Postby Anecdote » Wed Mar 08, 2006 4:36 pm

Aah, now we know 8O
An Itinerary in Light and Shadow Completed Dr Charles Stratton / Dr David Wheldon abx regime for aggressive secondary progressive MS in June 2007, after four years. Still improving with no relapses since starting. Can't run but can paint all day.
Anecdote
Family Elder
 
Posts: 2098
Joined: Thu Jun 17, 2004 3:00 pm
Location: Bedfordshire UK

Postby HarryZ » Wed Mar 08, 2006 6:29 pm

Ian,

bromley wrote:Harry Z,

This is yesterday's news - see drugs pipeline.

I expect you saw it late as you were on the phone to your broker ready to sell your Biogen shares.

Ian :D



Well, my prediction came true for Tysabri :) That's the easy part of the equation. I can imagine the logistical nightmare that Biogen/Elan are going to endure to operate the Tysabri Registry!

You know, when BioMS contacted me a number of years ago and advised me about this new drug, I should have invested in them :wink:

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2320
Joined: Tue May 25, 2004 3:00 pm
Location: London, ON, Canada


Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users